Based on results from the phase 3 AEGEAN trial, the U.S. FDA has approved neoadjuvant/adjuvant durvalumab for patients with resectable NSCLC with no known EGFR mutations or ALK rearrangements. Learn more: hmpgloballearningnetwork.com/site/onc/news/… #medtwitter #onctwitter #FDAapprovals

Caroline Schinke, MD, Myeloma Center at the UniversityOfArkansas for Medical Sciences, discusses long-term efficacy and safety results from the MonumenTAL-1 trials on of #talquetamab treatment among patients with multiple myeloma. Learn more: hmpgloballearningnetwork.com/site/onc-app/v… #MedTwitter

A recent study by Donna Catamero, Mount Sinai Health System and colleagues provides guidance on practical management of patients with R/R #MM receiving #talquetamab, based on experience from the MonumenTAL-1 trial. Learn more: hmpgloballearningnetwork.com/site/onc-app/a… #MedTwitter #hematology

Based on results from the MARIPOSA trial, the U.S. FDA has approved lazertinib plus amivantamab for patients with advanced NSCLC with EGFR mutations. Learn more: hmpgloballearningnetwork.com/site/onc/news/… #medtwitter #onctwitter #FDAapprovals

Are you ready? We are just under 2 months until we open the doors to #LLMCongress2024. If you have not registered yet, make sure to do so before the discounted rate ends on September 20. hmpglobalevents.com/llmcongress Joseph Mikhael The Leukemia & Lymphoma Society Follicular Lymphoma Foundation Lymphoma Research Foundation #hematology #oncology

Join us in Dallas on October 19-20 for the continuation of #GDUGI. Don't miss this unique opportunity to hear from leading experts, engage in dynamic discussions, and stay ahead of the latest advancements in colorectal cancers, gastroesophageal cancers and other GI malignancies.

As Michael Cecchini, MD, and coauthors concluded, these results yield "exceptional survival with high R0 resection rates for patients who completed per-protocol therapy." Learn more: hmpgloballearningnetwork.com/site/onc/news/… #medtwitter #onctwitter

According to a phase 1 study, the dosing of selumetinib with a low-fat meal had no clinically relevant impact on selumetinib exposure or GI tolerability among adolescent patients with NF1-PN. Learn more: hmpgloballearningnetwork.com/site/onc/news/… #medtwitter #onctwitter

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated advanced NSCLC. Learn more: hmpgloballearningnetwork.com/site/onc/news/… #medtwitter #onctwitter

According to Alexios Matikas, MD, PhD, and coauthors, "This is to our knowledge the first trial demonstrating improved outcomes with dose-dense chemotherapy.” Learn more: hmpgloballearningnetwork.com/site/onc/news/… #medtwitter #onctwitter

Meet some of the esteemed faculty speaking at hashtag#LLMCONGRESS2024 on Myeloma Day, Friday, October 18. Dive deep into Biology and Pathology with leading experts, and gain valuable insights tailored for clinicians. Don't miss out on this opportunity to enhance the care you

As Collin Blakely MD, PhD and coauthors concluded, "Treatment with neoadjuvant osimertinib in surgically resectable (stage IA-IIIA, AJCC V7) EGFR-mutated NSCLC did not meet its primary end point for MPR rate." Learn more: hmpgloballearningnetwork.com/site/onc/news/… #medtwitter #onctwitter

While vemurafenib did appear to be tolerable and offer a potential treatment option for pediatric patients with tumors harboring BRAF mutations, study authors noted, “further conclusions could not be established.” Learn more: hmpgloballearningnetwork.com/site/onc/news/… #medtwitter #onctwitter

According to Thomas J Ettrich, MD, and coauthors, "NIFE is the first prospective trial demonstrating efficacy of [nanoliposomal irinotecan with fluorouracil and leucovorin] in the first-line therapy setting." Learn more: hmpgloballearningnetwork.com/site/onc/news/… #medtwitter #onctwitter

While our name, the Lymphoma, Leukemia & Myeloma Congress, highlights three specific diagnoses, our scope extends far beyond. LL&M is committed to advancing research and treatment solutions across the spectrum of over 100 blood cancers. As we begin Blood Cancer Awareness Month

According to results from a phase 2 study, trastuzumab deruxtecan demonstrated promising activity among patients with HER2-expressing unresectable or recurrent biliary tract cancer. Learn more: hmpgloballearningnetwork.com/site/onc/news/… #medtwitter #onctwitter

#LLMCongress2024 faculty member Dr. Peter Martin was featured in a PBS story about the journey of a patient with mantle cell #lymphoma. Watch here: medicalstories.tv/title/mcl/ WCM Lymphoma Weill Cornell Medicine NewYork-Presbyterian

According to results from a phase 2 study, bintrafusp alfa demonstrated promising clinical activity among patients with recurrent or metastatic cervical cancer. Learn more: hmpgloballearningnetwork.com/site/onc/news/… #medtwitter #onctwitter

👀 Have you seen our #llmcongress2024 Meeting & Travel Guidebook Inside you will find: ⭐ Travel Information - including flight discount codes ⭐ Agenda Highlights ⭐ Must See Attractions ⭐ Registration Details View Now: nxtbook.com/hmpglobal/LLMC…

According to Alessandro Santin, MD, and coauthors, "[Sacituzumab govitecan] showed encouraging activity in a heavily pretreated patient population with advanced/metastatic [endometrial cancer]." Learn more: hmpgloballearningnetwork.com/site/onc/news/… #medtwitter #onctwitter